NASDAQ NMS - GLOBAL MARKET · INKT
+4.99% · +$0.5800 · Vol 11.8K
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
Mink Therapeutics Inc

Mink Therapeutics Inc

Biotechnology
$12.20
Card
Relationship Map

Veridion Score

BETALOW CONF · 6/6 factorsMethodology
INKT
Mink Therapeutics Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is INKT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading INKT catalysts
About Mink Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2021
Employees
15
Country
US

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$11.64
Day high
$12.20
Day low
$11.22
Previous close
$11.62
52W high
$16.30
-25.15% from high
52W low
$8.56
47% of range
Market cap
$62.3M
EPS
$-2.9000
Beta
0.64
Shares out
5.1M
Volume
11.8K
1.20× rel vol
Avg volume
9.8K
VWAP
$11.86
Price history computed in-house
1W
+8.25%
1M
+10.21%
3M
+12.24%
1Y
-18.12%
YTD
+9.42%
SMA 50 $11.31 · above
SMA 200 $11.45 · above
52W position 47%

INKT overview

Veridion Score
59
Registered · 2026-08-21
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around INKT.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading INKT Form 4 filings
Public disclosures

Congress activity in INKT

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for INKT in the cached public ledger.

Federal contracts

INKT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for INKT in this window.
Lobbying spend

INKT lobbying filings, year to date.

Registered lobbying filings matched to Mink Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for INKT in this window.
Loading news for INKT
Analyst ratings
Sovereign unlock shows live analyst consensus for INKT.
Options
Sovereign unlock shows live options positioning for INKT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.